Burkitt Lymphoma Treatment Market report provides key enumeration on the Market status of the Burkitt Lymphoma Treatment manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. The research was conducted using an objective combination of primary and secondary information including inputs from key participants in the Burkitt Lymphoma Treatment industry. It delivers important information to identify and analyse the market need, market Growth and competition.
The global Burkitt Lymphoma Treatment Market analysis further provides pioneering landscape of market along with market augmentation history and key development involved in the industry. The report also features comprehensive research study for high growth potential industries professional survey with market analysis. Burkitt Lymphoma Treatment Market report helps the companies to understand the market trends and future market prospective,opportunities and articulate the critical business strategies.
Overview
Burkitt lymphoma is a lymphatic system cancer that originates from aberrant B cells and has a fast development rate. Burkitt lymphoma produces lymph node swelling in the liver, brain, stem cells, and central nervous system, among other places. Burkitt lymphoma is a kind of non-Hodgkin lymphoma that is high-grade (NHL). Burkitt lymphoma is categorized by the World Health Organization as an endemic disease that affects children aged 4 to 7 years in Africa, a sporadic disease that occurs internationally, and an immunodeficiency-associated disease that affects individuals living with HIV/AIDS. Burkitt lymphoma accounts for 30 percent of juvenile malignancies and fewer than 1 percent of lymphoma incidences in adults, as per a Cancer Therapy Advisor study.
Drivers
Burkitt lymphoma is an AIDS-defining disease that is projected to develop more frequently in people living with HIV than in the general population, therefore, HIV is expected to boost growth of the global Burkitt lymphoma treatment market during the forecast period. According to the Burkitt Lymphoma Society, the disease affects around 40 percent of all children with non-Hodgkin lymphoma globally. It is also responsible for up to 40 percent of all non-Hodgkin lymphomas in HIV/AIDS individuals. Burkitt lymphoma (BL) is the most prevalent pediatric malignancy, according to the Cancer Therapy Advisor, with an infectious diseases 2-3 times greater in Sub-Saharan Africa, with an annual prevalence of 3–6 cases per 100,000 children each year.
Several government and non-government groups are working on research projects to develop effective therapies and raise awareness about the uncommon condition. The BLGSP (Burkitt Lymphoma Genome Sequencing Project) was started by the National Cancer Institute to look into potential genetic alterations in Burkitt lymphoma patients that might lead to better screening, diagnosis, and therapy. The Burkitt Lymphoma Society is a non-profit organization that supports and links patients and caretakers by linking individuals who have had effective Burkitt lymphoma treatment, therefore giving information and raising awareness about the uncommon medical illness.
During the forecast period, the existence of prospective treatments for the prevention of Burkitt lymphoma is projected to boost market growth. Tractinostat in conjunction with Valganciclovir has begun a Phase 1 b/2 study at Viracta Therapeutics, Inc. for Epstein-Barr virus-positive (EBV+) lymphomas. EBV-associated malignancies are expected to cause about 200,000 new cases and over 140,000 deaths per year, according to Cancer Research U.K. The National Cancer Institute has begun Phase 1 clinical studies for blinatumomab, a recombinant bispecific antibody targeted towards C-19, in conjunction with Lenalidomide in patients with relapsed or refractory non-lymphoma.
Regional Analysis
Due to the growing incidence of lymphoma throughout the forecast period, North America is projected to retain a leading position in the global Burkitt lymphoma treatment market. As per a poll performed by WebMD, LLC in 2015, around 1,200 individuals are diagnosed each year in the U.S., with 59 percent of patients aged 40 and over.
Due to the rising frequency of spontaneous Burkitt lymphoma in the U.K., the European Burkitt lymphoma treatment market is projected to develop rapidly. According to a study conducted by the Lymphoma Action Organization in 2015, about 210 people in the U.K. are diagnosed with Burkitt lymphoma each year.
Competitive Landscape
The global Burkitt lymphoma treatment market’s major companies are developing medicines to meet the growing unmet requirements of patients with relapsed or refractory Burkitt lymphoma. In 2015, Servier and Pfizer Inc. launched a Phase 1 trial for gene-edited allogeneic CAR19 T-cells in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
Major companies contributing in the global Burkitt lymphoma treatment market are Merck KGaA, Pfizer, Inc., Eisai Inc., Sanofi Pasteur, Novartis AG, AbbVie Inc., Boehringer Ingelheim GmbH, Cellerant Therapeutics, Inc., Karyopharm Therapeutics, Inc., and Seattle Genetics, Inc.AbbVie Inc.
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/1547
Reasons to Purchase this Report
• Current and future of global Burkitt Lymphoma Treatment Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
About Us
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact Us
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837